TCE

Pangaea Logistics Solutions Ltd. Reports Financial Results for the Quarter Ended March 31, 2024

Retrieved on: 
木曜日, 5月 9, 2024
Port of Palm Beach, COA, Handymax, TCE, Partnership, Transport, Acquisition, Eastern Time Zone, Adjustment, Lunar phase, Growth, Airline

NEWPORT, R.I., May 9, 2024 /PRNewswire/ -- Pangaea Logistics Solutions Ltd. ("Pangaea" or the "Company") (Nasdaq: PANL), a global provider of comprehensive maritime logistics solutions, announced today its results for the three months ended March 31, 2024.

Key Points: 
  • NEWPORT, R.I., May 9, 2024 /PRNewswire/ -- Pangaea Logistics Solutions Ltd. ("Pangaea" or the "Company") (Nasdaq: PANL), a global provider of comprehensive maritime logistics solutions, announced today its results for the three months ended March 31, 2024.
  • As of March 31, 2024, the Company had $95.9 million in cash and cash equivalents.
  • "In 2024, our capital deployment priorities are on the build-out of our on-shore logistics business, together continued investment in our fleet.
  • The Company's management team will host a conference call to discuss the Company's financial results on Friday, May 10, 2024 at 8:00 a.m., Eastern Time (ET).

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
木曜日, 5月 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
木曜日, 5月 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
木曜日, 5月 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
木曜日, 5月 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
水曜日, 5月 8, 2024
MSD, Investment, Pancreatic cancer, Research, TCE, CRC, Trial of the century, Webcast, Drug discovery, EGFR, Bladder cancer, Cancer, CRS, Cytokine, Tumor microenvironment, ADC, Vomiting, Therapeutic index, Kidney, Bristol Myers Squibb, Therapy, Biotechnology, Spacecraft, SAN, Arthralgia, Safety, Pembrolizumab, RECIST, Arthritis, GLP, Melanoma, BMS, Toxicology, CD3, EDT, Itch, Merck & Co., PDT, Camptothecin, Patient, Rash, Head, Epithelial cell adhesion molecule, Amgen, Pharmaceutical industry

Initial data anticipated in 2025 -

Key Points: 
  • Initial data anticipated in 2025 -
    - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT -
    SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today reported first quarter 2024 financial results and provided a business update.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • The cash balance as of March 31, 2024, does not include the $10.0 million of Astellas milestone achievements earned in the first quarter of 2024.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

International Seaways Reports First Quarter 2024 Results

Retrieved on: 
水曜日, 5月 8, 2024
Maritime, Energy, Transport, Oil, Gas, Sale, VLCC, Safety, RCF, TCE, Depreciation, Carbon footprint, History, Exercise, INSW, Line of credit, Share repurchase, LR2, GAAP, Video game

International Seaways, Inc. (NYSE: INSW) (the “Company,” “Seaways,” or “INSW”), one of the largest tanker companies worldwide providing energy transportation services for crude oil and petroleum products, today reported results for the first quarter 2024.

Key Points: 
  • International Seaways, Inc. (NYSE: INSW) (the “Company,” “Seaways,” or “INSW”), one of the largest tanker companies worldwide providing energy transportation services for crude oil and petroleum products, today reported results for the first quarter 2024.
  • Sold a 2009-built MR for net proceeds of $23 million after fees and commissions during the second quarter of 2024.
  • “Following a record year for Seaways, our first quarter earnings increased over the prior quarter and marked the eighth consecutive quarter of strong earnings,” said Lois K. Zabrocky, International Seaways President and CEO.
  • The Company will host a conference call to discuss its first quarter 2024 results at 9:00 a.m. Eastern Time on Wednesday, May 8, 2024.

Medigene AG reports Financial Results and Business Update for Q1 2024

Retrieved on: 
金曜日, 4月 26, 2024
Prospectus, Synovial sarcoma, Tissue, Federal Gazette, TCE, Partnership, EUR, Stomach, European, Exercise, Frankfurt Stock Exchange, BioNTech, Regeneron Pharmaceuticals, Patient, Supervisory board, Toxicity, IIT, AACR, Senior, TCR, Annual general meeting, Annual report, Cancer, Ovarian cancer, Pharmaceutical industry

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024.
  • The full Quarterly Statement Q1 2024 can be downloaded here: https://medigene.com/investors-media/reports-presentations/ .
  • The financial performance in Q1 2024 was in line with the Executive Management Board’s expectations.
  • The subscription period for the new shares commenced on April 24, 2024 and ends on May 7, 2024 at 24:00 hours (CEST).

Financial Institutions, Inc. Announces First Quarter 2024 Results

Retrieved on: 
木曜日, 4月 25, 2024
Benefit, Common equity, Sale, NFP, Common, Federal Reserve, Investment, Nature, Bank, TCE, Tier 1 capital, As a service, Insurance, Financial institution, Risk management, Environment, Computer, Income tax, Risk-weighted asset, Acquisition, Community Reinvestment Act, Loss, Marketing, Bank statement, Five Star Bank, Community, Growth, Earnout, Video game

Net income was $2.1 million in the first quarter of 2024, compared to $9.8 million in the fourth quarter of 2023 and $12.1 million in the first quarter of 2023.

Key Points: 
  • Net income was $2.1 million in the first quarter of 2024, compared to $9.8 million in the fourth quarter of 2023 and $12.1 million in the first quarter of 2023.
  • First quarter 2024 financial results were negatively impacted by the Company's previously disclosed deposit-related fraud event, which was the primary driver of noninterest expense variances from the linked and year-ago periods.
  • Net interest margin was 2.78% in the current quarter and the fourth quarter of 2023, and 3.09% in the first quarter of 2023.
  • The effective tax rate was 14.7% for the first quarter of 2024, 34.5% for the fourth quarter of 2023, and 18.7% for the first quarter of 2023.

QCR Holdings, Inc. Announces Net Income of $26.7 Million for the First Quarter of 2024

Retrieved on: 
火曜日, 4月 23, 2024
Sale, Central Time, Housing, News, TCE, Webcast, NIM, LIHTC, NPAS, GAAP, Growth, QCR Holdings, Bank

MOLINE, Ill., April 23, 2024 (GLOBE NEWSWIRE) -- QCR Holdings, Inc. (NASDAQ: QCRH) (the “Company”) today announced quarterly net income of $26.7 million and diluted earnings per share (“EPS”) of $1.58 for the first quarter of 2024, compared to net income of $32.9 million and diluted EPS of $1.95 for the fourth quarter of 2023.

Key Points: 
  • Net interest income for the first quarter of 2024 totaled $54.7 million, a decrease of $1.0 million from the fourth quarter of 2023.
  • However, the Company’s net interest income driven by core activity saw growth of approximately $1.2 million during the first quarter, led by continued expansion in loan and investment yields.
  • The Company generated $16.5 million of capital markets revenue in the quarter, as compared to the record $37.0 million in the prior quarter.
  • Wealth management revenue was $4.3 million for the quarter, up 16% on an annualized basis from $4.1 million in the prior quarter.